Pelaia, C.; Pelaia, G.; Crimi, C.; Maglio, A.; Armentaro, G.; Calabrese, C.; Sciacqua, A.; Gallelli, L.; Vatrella, A.
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines 2022, 10, 974.
https://doi.org/10.3390/vaccines10060974
AMA Style
Pelaia C, Pelaia G, Crimi C, Maglio A, Armentaro G, Calabrese C, Sciacqua A, Gallelli L, Vatrella A.
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines. 2022; 10(6):974.
https://doi.org/10.3390/vaccines10060974
Chicago/Turabian Style
Pelaia, Corrado, Giulia Pelaia, Claudia Crimi, Angelantonio Maglio, Giuseppe Armentaro, Cecilia Calabrese, Angela Sciacqua, Luca Gallelli, and Alessandro Vatrella.
2022. "Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13" Vaccines 10, no. 6: 974.
https://doi.org/10.3390/vaccines10060974
APA Style
Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Armentaro, G., Calabrese, C., Sciacqua, A., Gallelli, L., & Vatrella, A.
(2022). Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 10(6), 974.
https://doi.org/10.3390/vaccines10060974
